Saniona AB
STO:SANION

Watchlist Manager
Saniona AB Logo
Saniona AB
STO:SANION
Watchlist
Price: 8.12 SEK 0.62% Market Closed
Market Cap: 903.3m SEK
Have any thoughts about
Saniona AB?
Write Note

Saniona AB
Cash from Investing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Saniona AB
Cash from Investing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Investing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Saniona AB
STO:SANION
Cash from Investing Activities
-kr129k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Genmab A/S
CSE:GMAB
Cash from Investing Activities
-kr9.6B
CAGR 3-Years
-61%
CAGR 5-Years
-40%
CAGR 10-Years
-27%
Zealand Pharma A/S
CSE:ZEAL
Cash from Investing Activities
-kr7.5B
CAGR 3-Years
-1 389%
CAGR 5-Years
-70%
CAGR 10-Years
N/A
Ascendis Pharma A/S
NASDAQ:ASND
Cash from Investing Activities
€13.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
B
Bavarian Nordic A/S
CSE:BAVA
Cash from Investing Activities
-kr1.9B
CAGR 3-Years
-19%
CAGR 5-Years
N/A
CAGR 10-Years
-39%
Bioporto A/S
CSE:BIOPOR
Cash from Investing Activities
-kr246k
CAGR 3-Years
46%
CAGR 5-Years
30%
CAGR 10-Years
15%
No Stocks Found

Saniona AB
Glance View

Market Cap
903.3m SEK
Industry
Biotechnology

Saniona AB engages in the research and development on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases, and treatment of pain. The company operates in the area of drugs targeting ion channels to develop therapeutics for pain, central nervous system, and inflammatory or autoimmune diseases. The firm develops a technology platform which enables investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors and potassium channels. The clinical pipeline includes: AN788, a clinical candidate for second line treatment of major depressive disorder (MDD); AN761, to be developed for cognition deficits in schizophrenia and Alzheimer's disease; AN363, a candidate for treatment of pain disorders; and AN346, an anti-inflammatory treatment in inflammatory bowel disease (IBD); as well as several other projects. The firm is engaged in partnerships with Janssen Pharmaceuticals Inc, Pfizer Inc and Atlas Venture Inc.

SANION Intrinsic Value
3.56 SEK
Overvaluation 56%
Intrinsic Value
Price

See Also

What is Saniona AB's Cash from Investing Activities?
Cash from Investing Activities
-129k SEK

Based on the financial report for Jun 30, 2024, Saniona AB's Cash from Investing Activities amounts to -129k SEK.

What is Saniona AB's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 1Y
85%

Over the last year, the Cash from Investing Activities growth was 85%.

Back to Top